Ace inhibitors and angiotensin receptor blockers
Searched over 200M research papers
Summary
10 papers analyzed
These studies suggest ACE inhibitors and ARBs reduce the incidence of type 2 diabetes, cardiovascular events, and kidney failure, with ACE inhibitors potentially being the first choice for chronic kidney disease, while combination therapy may benefit diabetic nephropathy and proteinuric renal disease.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
The Role of ACE Inhibitors and Angiotensin Receptor Blockers in Health Management
Prevention of Type 2 Diabetes with ACE Inhibitors and ARBs
Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) have been shown to play a significant role in preventing the onset of type 2 diabetes mellitus. A meta-analysis of 12 randomized controlled trials revealed that ACE inhibitors and ARBs reduced the incidence of newly diagnosed diabetes by 27% and 23%, respectively, with a pooled reduction of 25%. This suggests that these medications could be beneficial for patients with pre-diabetic conditions such as metabolic syndrome, hypertension, impaired fasting glucose, family history of diabetes, obesity, congestive heart failure, or coronary heart disease.
Cardiovascular Outcomes in High-Risk Patients
In high cardiovascular (CV) risk patients without heart failure (HF), both ACE inhibitors and ARBs have been found to reduce the risk of major cardiovascular events. A network meta-analysis of 27 randomized controlled trials showed no significant differences between ACE inhibitors and ARBs in preventing CV death, myocardial infarction (MI), and stroke. Another meta-analysis confirmed that ACE inhibitors significantly reduced the risk of the composite outcome of CV death, MI, and stroke, as well as all-cause death, new-onset HF, and new-onset diabetes mellitus. ARBs also reduced the risk of the composite outcome and new-onset diabetes mellitus, making them a valuable option for patients who cannot tolerate ACE inhibitors.
Renal Protection in Chronic Kidney Disease
For patients with chronic kidney disease (CKD), ACE inhibitors and ARBs have been shown to reduce the risk of kidney failure and major cardiovascular events. A Bayesian network meta-analysis of 119 randomized controlled trials indicated that ACE inhibitors and ARBs reduced the odds of kidney failure by 39% and 30%, respectively, compared to placebo. Both drug classes also produced significant reductions in major cardiovascular events, although ACE inhibitors were associated with a higher probability of reducing all-cause mortality compared to ARBs.
Combination Therapy in Proteinuric Renal Disease
Combination therapy with an ACE inhibitor and an ARB has been explored for its potential benefits in proteinuric renal disease. A systematic review and meta-analysis of 21 randomized controlled studies found that combination therapy resulted in a significant decrease in proteinuria compared to ACE inhibitor monotherapy, without clinically meaningful changes in serum potassium levels or glomerular filtration rates. This suggests that combination therapy could be beneficial in managing proteinuric renal disease, although further long-term studies are needed to confirm these findings.
Impact on Normotensive Atherosclerotic Patients
ACE inhibitors and ARBs have also been found to be beneficial in normotensive patients with or at increased risk for atherosclerotic vascular disease. A collaborative meta-analysis of randomized trials involving 80,594 patients showed that these medications reduced the composite primary outcome of cardiovascular death, non-fatal MI, or non-fatal stroke by 11%, with consistent benefits across all subgroups, including those without systolic heart failure or diabetes.
Conclusion
ACE inhibitors and ARBs are valuable medications with a broad range of benefits, including the prevention of type 2 diabetes, reduction of cardiovascular events, and protection against kidney failure in CKD patients. While both drug classes offer similar benefits in many areas, ACE inhibitors may have a slight edge in reducing all-cause mortality. Combination therapy with both ACE inhibitors and ARBs shows promise in managing proteinuric renal disease, although more research is needed to establish long-term benefits. Overall, these medications should be considered in various patient populations to optimize health outcomes.
Sources and full results
Most relevant research papers on this topic
